As of July 15, 2014, Zalicus Inc. was acquired by EPIRUS Biopharmaceuticals, Inc., in a reverse merger transaction. Zalicus Inc., a biopharmaceutical company, discovers and develops novel treatments for patients suffering from pain. The company develops Z944, a novel oral T-type calcium channel blocker that has completed Phase Ib clinical studies for the treatment of pain indications. It is also engaged in research and preclinical development activities on its selective ion channel modulators targeting the Nav1.7 sodium channel for the treatment of pain. The company has collaboration agreements with Mallinckrodt Inc.; Fovea Pharmaceuticals SA; Institutes of BioMedical Research, Inc.; Amgen I...
245 First Street
Cambridge, MA 02142
Founded in 2000
Zalicus Inc. Reports Unaudited Earnings Results for the Quarter Ended March 31, 2014
Jul 15 14
Zalicus Inc. reported consolidated unaudited earnings results for the quarter ended March 31, 2014. For the quarter, the company reported total revenue of $1,603,000 compared with $14,731,000 for the same period last year. Loss from operations was $3,488,000 compared with $37,210,000 for the same period last year. Loss before income taxes was $3,790,000. Net loss was $3,790,000 or $0.15 basic and diluted per share compared with $38,617,000 or $1.68 basic and diluted per share for the same period last year. Adjusted loss from operations was $4,279,000 compared with $41,311,000 for the same period last year. Adjusted loss before income taxes before income taxes was $4,305,000. Adjusted net loss was $4,305,000 or $0.16 basic and diluted per share compared with $41,612,000 or $1.81 basic and diluted per share for the same period last year.
Zalicus Inc.(NasdaqCM:ZLCS) dropped from NASDAQ Composite Index
Jul 15 14
Zalicus Inc. will be removed from the NASDAQ Composite Index.
Fovea Pharmaceuticals Enters into Agreement to Terminate Second Amended and Restated License Agreement
Jul 2 14
Zalicus Inc. and Fovea Pharmaceuticals on June 30, 2014, entered into an agreement pursuant to which the parties mutually agreed to terminate that second amended and restated license agreement, dated July 22, 2009, between the parties. Following this termination, Zalicus assigned certain of its patents which had previously been licensed under the 2009 Agreement to a third party controlled by certain former owners of Fovea. This third party may exploit these patent rights independently or in conjunction with another third party.